Absci Corp Stock Price, News & Analysis

Absci Corporation (Nasdaq: ABSI) announced its participation in the Berenberg Discover AI Seminar on November 29, 2022, at 10:00 a.m. Eastern Time, in New York. The company, a pioneer in generative AI drug creation, will engage in a fireside chat during the event. Absci focuses on drug and target discovery using deep learning AI and synthetic biology to produce innovative protein-based therapeutics. Their Integrated Drug Creation™ platform streamlines the process from identifying drug targets to generating manufacturing cell lines.

Absci Corporation (Nasdaq: ABSI), a leader in generative AI drug creation, announced its participation in the Piper Sandler Healthcare Conference on December 1, 2022, at 8:30 a.m. ET. The presentation will be accessible via a live and archived webcast on the company's investor relations website. Absci utilizes its Integrated Drug Creation™ platform, which combines deep learning AI and synthetic biology, to enhance protein therapeutic development. The company strives to advance medicine through innovative drug discovery.

Absci Corporation (Nasdaq: ABSI) reported strong third-quarter results, showcasing progress in drug discovery through its Merck collaboration. Total revenue reached $2.4 million, up from $1.5 million in Q3 2021, driven by milestones in its non-standard amino acid (nsAA) technology. Operating expenses increased to $27.6 million, including $2.7 million in severance costs. Cash reserves decreased to $181.3 million. The company expects a total cash decrease of approximately $105 million for 2022, refining their prior estimate. Absci continues to prioritize strategic initiatives, projecting sufficient cash into late 2025.

Absci Corporation (Nasdaq: ABSI) announced its participation in the Stifel Healthcare Conference in New York on November 16, 2022, at 4:10 p.m. ET. The company, known for leveraging generative AI and biological data in therapeutic design, will host a fireside chat, accessible via their investor relations website. Absci focuses on drug discovery and the development of protein-based therapeutics using its Integrated Drug Creation™ platform, aiming to enhance the creation of innovative drugs such as Bionic™ proteins.

Absci Corporation (Nasdaq: ABSI) has appointed Dan Rabinovitsj, a technology veteran and Meta Connectivity VP, to its Board of Directors. With over 30 years of experience in technology scaling and business model innovation, Rabinovitsj aims to enhance Absci’s generative AI-driven drug creation capabilities. His addition follows Dr. Andreas Busch's transition to Chief Innovation Officer. Rabinovitsj’s background includes key roles in major tech firms, which the CEO believes will be invaluable as Absci seeks to create biologics more efficiently.

Absci Corporation (Nasdaq: ABSI) announced participation in the Credit Suisse Annual Healthcare Conference to be held in Rancho Palos Verdes, CA, on November 10, at 9:10 a.m. PT. The event will feature a fireside chat with Absci management, which can be accessed via a live and archived webcast on their investor relations website. Absci focuses on protein drug creation, utilizing generative AI and biological data to advance therapeutic development.

Absci Corporation (Nasdaq: ABSI) has appointed Dr. Andreas Busch as Chief Innovation Officer, transitioning from the Board of Directors to the executive team. With extensive experience in R&D at major pharma companies, Dr. Busch has facilitated the development of over 10 FDA-approved drugs. His role will involve leading R&D and technical operations, enhancing Absci's drug creation capabilities through generative AI and high-throughput data technologies. The company aims to revolutionize drug discovery and improve access to effective therapeutics for patients.

Absci Corporation (Nasdaq: ABSI) announced its participation in the Morgan Stanley Annual Healthcare Conference in New York on September 14, 2022. The company will engage in a fireside chat scheduled for 4:05 PM ET. Interested parties can access a live and archived webcast via the company’s investor relations website. Absci focuses on drug and target discovery using deep learning AI and synthetic biology, aiming to enhance protein therapeutic potentials.

Absci Corporation (Nasdaq: ABSI) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022. The company will present in a fireside chat at 7:00 a.m. PT (10:00 a.m. ET). Interested parties can access the live and archived webcast on its investor relations website. Absci specializes in drug and target discovery using deep learning AI and synthetic biology, aiming to expand therapeutic proteins' potential through its Integrated Drug Creation™ Platform.